ALEMBIC THERAP
PharmaALEMBIC THERAP is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Ophthalmology. Key products include NUVESSA.
ALEMBIC THERAP's Key Drugs
ALEMBIC THERAP's core commercial portfolio centers on PIVYA, NUVESSA, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
ALEMBIC THERAP's Recent FDA Approvals
New NDA/BLA approvals for ALEMBIC THERAP over the last two years — novel drugs only, excluding generics and label supplements.
ALEMBIC THERAP's Therapeutic Areas
ALEMBIC THERAP's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALEMBIC THERAP's Top Competitors
ALEMBIC THERAP's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH AND LOMB INC, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALEMBIC THERAP Pipeline Snapshot
ALEMBIC THERAP has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PIVYA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling